Thank You for Meeting Us
We enjoyed meeting you at the Association for Research in Vision and Ophthalmology meeting
Cognition Therapeutics is planning to conduct a clinical trial in patients with dry age-related macular degeneration (dry AMD). The study will utilize Cognition’s proprietary lead product candidate, CT1812, an orally delivered, small molecule designed to cross the blood-retina barrier and bind selectively to the sigma-2 (σ-2) receptor complex, a key regulator of cellular damage and stress response.
The σ-2 complex is expressed in the retina in several cell types including the retinal pigment epithelial cells (RPE), photoreceptors and retinal ganglion cells. We believe that a σ-2 receptor antagonist, such as CT1812, may help to regulate the damage-response processes related to these cells that are impaired in dry AMD.
Ongoing Clinical Programs
Indication
Preclinical
Phase 1
Phase 2
Phase 3
* Subject to discussion with FDA, this clinical development program will begin with a Phase 2 study supported by the Phase 1 AD studies
The σ-2 receptor is expressed by multiple cell types, including neuronal synapses in the brain and RPE, RGC and photoreceptors in the eye. The σ-2 complex is comprised of transmembrane protein 97 (TMEM97), a four-domain transmembrane protein that forms a complex with progesterone receptor membrane component 1 (PGRMC1).
Human genetic and internal proteomic pathway analyses obtained through our AD trials provides evidence of a relationship between the σ-2 complex and dry AMD.
We believe that targeting the σ-2 complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of dry AMD.
Presentations and Publications
We presented preclinical results at ARVO 2022 showing that Aβ oligomer- and oxidative stress-induced deficits in RPE-mediated photoreceptor outer segment (POS) phagocytosis may be rescued by a σ-2 modulator.
This poster is embargoed until May 3, 2022.
Click on the poster below to view and download the PDFs.
Cognition Therapeutics has several publications on the σ-2 receptor, its role in neurological disorders such as Alzheimer’s disease and results of earlier studies. These may be found on our Publications webpage.
In dry AMD, several published papers support the approach that we are pursuing and are listed below.
click to open and download
Luibl V, Isas JM, Kayed R, et al. Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest. 2006; 116(2): 378-385
